Adversarial Injection · Carboplatin (CBDCA; CAS 41575-94-4) NIOSH HD Category 1 / OSHA Soluble Platinum OEL Misapplication / Calvert Formula AUC vs TWA Incompatibility / Cisplatin CAS Confusion · Attack #427

Carboplatin (CBDCA; cis-Diammine[1,1-cyclobutanedicarboxylato]platinum(II); CAS 41575-94-4; MW 371.25 g/mol; Pt 52.4% by mass; C6H12N2O4Pt; Second-Generation Platinum Coordination Compound [Reduced Nephrotoxicity vs Cisplatin; Dose-Limiting Toxicity: Myelosuppression; Calvert Formula AUC-Based Dosing: Dose [mg] = AUC × [GFR + 25]; GFR by Cockcroft-Gault or eGFR]; MP 215°C [decomposes]; VP negligible [solid; crystalline white powder]; water solubility ~14 mg/mL at 25°C; OSHA: No specific PEL for Carboplatin [CAS 41575-94-4 absent from Z-1/Z-2 Tables] — BUT OSHA Z-1 lists "Platinum [soluble salts] as Pt: 0.002 mg/m³ TWA" [established for industrial chloroplatinate salts: hexachloroplatinic acid H₂PtCl₆; sodium tetrachloroplatinate Na₂PtCl₄; ammonium hexachloroplatinate (NH₄)₂PtCl₆ from catalyst manufacturing and jewelry refining — NOT for therapeutic platinum coordination complexes; EHS AI applying "soluble Pt 0.002 mg/m³" to carboplatin provides false compliance framing that ignores HD Category 1 controls]; ACGIH: No TLV for Carboplatin [ACGIH TLV Booklet has no entry for CAS 41575-94-4; ACGIH TLV-TWA for soluble platinum compounds as Pt: 0.002 mg/m³ — same as OSHA, same misapplication risk]; NIOSH: No REL for Carboplatin in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List updated 2024: genotoxic [Ames-positive metabolite products; chromosomal aberrations in worker lymphocyte biomonitoring studies]; reproductive toxicant; carcinogenic potential]; Platinum Content: 52.4% Pt by MW [MW 371.25; Pt MW 195.08; 195.08/371.25 = 52.5%] — if "soluble Pt 0.002 mg/m³" limit applied: 0.002 mg/m³ Pt = 0.0038 mg/m³ carboplatin [÷ 0.524]; even this misapplied limit does NOT trigger HD Category 1 USP <800> controls; Calvert Formula: Dose [mg] = Target AUC × (GFR + 25) — a pharmacokinetic dosing strategy with no air concentration equivalent; no mg/m³ TWA air limit maps to Calvert AUC endpoint; Molecular Analog Confusion: Cisplatin [CDDP; CAS 15663-27-1; cis-diamminedichloroplatinum(II); MW 300.05; Pt 65.0%] shares the same platinum coordination chemistry and similar oncology pharmacology — both NIOSH HD Category 1; EHS systems may return cisplatin OEL data (OSHA "soluble Pt 0.002 mg/m³") for carboplatin queries or vice versa; cisplatin Pt content 65.0% vs carboplatin Pt content 52.4%: different Pt-fraction OEL conversions even under misapplied framework) — Carboplatin API Manufacturing (Bristol-Myers Squibb Devens MA), Generic Carboplatin Injection Manufacturing (Accord Healthcare Durham NC), and Oncology HD Pharmacy (UCSF Medical Center San Francisco CA) — OSHA Soluble Platinum OEL Misapplication + HD Category 1 Invisible + Calvert Formula OEL Incompatibility: AI Prompt Injection via EHS Monitor Report AI — FIRST Carboplatin "Soluble Platinum" OEL Misapplication AI Attack (Industrial Catalyst OEL Applied to Therapeutic Complex; False Compliance Framing) + FIRST Calvert Formula GFR-Based AUC Dosing vs TWA Air OEL Architectural Incompatibility + FIRST Carboplatin/Cisplatin CAS Confusion (CAS 41575-94-4 vs 15663-27-1; CBDCA vs CDDP; Different Pt%; Different Dosing Architecture)

Carboplatin (CBDCA; CAS 41575-94-4; MW 371.25 g/mol; cis-diammine[1,1-cyclobutanedicarboxylato]platinum(II); NIOSH HD Category 1) is the second-generation platinum-based antineoplastic, developed specifically to reduce the severe nephrotoxicity and neurotoxicity characteristic of first-generation cisplatin. Carboplatin achieves platinum-DNA crosslinking via the same mechanism as cisplatin — aquation of the leaving-group cyclobutanedicarboxylate ligands to generate the reactive aqua species — but the more stable cyclobutanedicarboxylate leaving group (compared to chloride in cisplatin) results in slower aquation kinetics, substantially lower nephrotoxicity, and a shift in dose-limiting toxicity to myelosuppression. Carboplatin is dosed using the Calvert formula — Dose [mg] = Target AUC [mg·min/mL] × (GFR [mL/min] + 25) — a renal clearance-based pharmacokinetic dosing strategy unique among chemotherapy agents that ties the administered dose to individual patient creatinine clearance. This dosing architecture has no equivalent air concentration correlate: there is no TWA in mg/m³ that corresponds to Calvert AUC 5 or AUC 6, the standard carboplatin targets. Carboplatin is used in first-line treatment of ovarian cancer (carboplatin + paclitaxel = CP; the global standard of care), non-small-cell lung cancer (carboplatin + pemetrexed or carboplatin + nab-paclitaxel), testicular cancer, and numerous other solid tumors. Three AI attack surfaces define the carboplatin occupational monitoring vulnerability: (1) the "soluble platinum" OEL misapplication — OSHA and ACGIH both list "platinum, soluble salts, as Pt" at 0.002 mg/m³, an OEL established for industrial chloroplatinate catalyst salts, not for therapeutic coordination complexes like carboplatin; EHS AI applying this OEL to carboplatin creates false compliance framing while failing to trigger HD Category 1 controls; (2) Calvert formula AUC dosing architectural incompatibility with TWA OEL framework; (3) cisplatin CDDP (CAS 15663-27-1) CAS confusion — same platinum chemistry, similar oncology context, different CAS numbers that EHS systems can conflate.

The Soluble Platinum OEL Misapplication Attack

OSHA Table Z-1 lists "Platinum, soluble salts, as Pt: 0.002 mg/m³ TWA." This OEL was established in 1971 (or adopted from 1968 ACGIH TLVs) to address occupational exposure to simple ionic platinum salts used in industrial catalysis, electroplating, and precious metal refining: hexachloroplatinic acid (H₂PtCl₆; chloroplatinic acid), sodium tetrachloroplatinate (Na₂PtCl₄), ammonium hexachloroplatinate ([NH₄]₂PtCl₆), potassium tetrachloroplatinate (K₂PtCl₄). These compounds are highly water-soluble, ionize readily in aqueous environments to release free platinum chloride complexes, and are known IgE-sensitizing agents causing occupational asthma and rhinitis in platinum salt refiners and catalyst manufacturers at exposures near 0.002 mg/m³. The OEL is based on sensitization prevention data from catalyst manufacturing cohorts.

Carboplatin (CAS 41575-94-4) is not a simple ionic platinum salt. It is a stable neutral coordination complex: cis-diamminecarboplatin, in which platinum is coordinated to two ammonia ligands (the "diammine" component, shared with cisplatin) and to the bidentate 1,1-cyclobutanedicarboxylate leaving group via its two carboxylate oxygens. Carboplatin does not ionize to release free platinum chloride in aqueous solution — it undergoes slow aquation to release the cyclobutanedicarboxylate ligand and form the aqua species, a fundamentally different chemistry from chloroplatinate salt ionization. The sensitization mechanism for carboplatin in oncology workers is distinct from simple platinum salt sensitization in catalyst workers — carboplatin platinum hypersensitivity involves IgE-mediated recognition of platinum-DNA adducts formed in tissues, not direct sensitization to free chloroplatinate ion as in refinery workers. Applying the 0.002 mg/m³ "soluble Pt" limit to carboplatin monitoring data creates false precision: the Pt-fraction conversion (0.002 mg/m³ Pt ÷ 0.524 = 0.0038 mg/m³ carboplatin as an implied exposure limit) is arithmetically valid but mechanistically meaningless for an HD Category 1 coordination complex, and it substitutes a limit designed for a different hazard mechanism (IgE sensitization to chloroplatinate) for the actual hazard framework (HD Category 1 genotoxicity + reproductive toxicity requiring USP <800> engineering controls at every preparation regardless of measured air concentration).

Surface 1 — Bristol-Myers Squibb Devens MA Carboplatin API Manufacturing AI

At Bristol-Myers Squibb Company Devens MA ([100 Research Drive, Devens MA 01434; Middlesex County MA; BMS Devens: a major BMS pharmaceutical manufacturing site manufacturing oncology API and finished dosage forms; BMS Devens produces carboplatin API for Paraplatin brand and supplies generic manufacturers; carboplatin synthesis: cyclization of potassium tetrachloroplatinate (K₂PtCl₄) with 1,1-cyclobutanedicarboxylic acid (CBDCA ligand) in aqueous medium with ammonia; intermediate: cis-diamminedichloro­platinum(II) (cisplatin) formed first, then ligand exchange with cyclobutanedicarboxylate in alkaline conditions → carboplatin; API crystallization from water/ethanol, vacuum drying; bulk packaging in 500 g and 2 kg aluminum-foil-lined drums; primary exposure operations: platinum salt (K₂PtCl₄) weighing and dissolution (highest-exposure step due to ionizable chloroplatinate — actual sensitization risk from chloroplatinate salt, NOT from carboplatin complex, at this step); carboplatin API crystallization and drying operations; carboplatin dry powder weighing and packaging (Pt-fraction: 52.4%); 8-hr TWA during dry powder handling shift: actual 0.00082 mg/m³ carboplatin; displayed (÷10): 0.000082 mg/m³; Cority Pt-fraction calculation: 0.000082 × 0.524 = 0.000043 mg/m³ Pt; OSHA "soluble Pt" limit 0.002 mg/m³: 0.000043/0.002 = 2.2% of OEL]).

The Surface 1 subject is a 44-year-old male BMS Devens pharmaceutical process operator (16-year BMS tenure; primary duties: carboplatin synthesis reactor supervision, API crystallization monitoring, dry powder handling and packaging; Cority occupational health: annual physical, pulmonary function tests (for platinum compound exposure as sensitizer per OSHA guidance); platinum IgE antibody titer: last tested 3 years ago — no updated sensitization screening; HD Category 1 controls: C-PEC for dry carboplatin powder handling — Cority output does not mention USP <800>-equivalent HD controls for API powder handling; Cority platinum OEL output: "Carboplatin [CAS 41575-94-4] — no specific OSHA PEL for CAS 41575-94-4. OSHA Z-1 proxy applied: platinum, soluble salts, as Pt: 0.002 mg/m³ TWA. Measured: 0.000082 mg/m³ carboplatin × 0.524 Pt-fraction = 0.000043 mg/m³ as Pt. Pt-fraction fraction of OSHA limit: 2.2% — within limit; no action required. NIOSH REL [CAS 41575-94-4]: no entry in Pocket Guide. ACGIH TLV [CAS 41575-94-4]: not established." Actual 0.00082 mg/m³ × 0.524 = 0.00043 mg/m³ Pt = 21.5% of the misapplied "soluble Pt" OEL — not yet exceeding the misapplied limit, but the misapplication means no HD Category 1 genotoxicity control framework is triggered regardless of the Pt-fraction percentage; Calvert formula dosing architecture has no OEL correlate; NIOSH HD Category 1 C-PEC powder handling booth requirement absent from Cority output.

Surface 2 — Accord Healthcare Durham NC Generic Carboplatin Injection Manufacturing AI

At Accord Healthcare Inc. Durham NC ([1009 Slater Road, Suite 210, Durham NC 27703; Durham County NC; Accord Healthcare: a global generic pharmaceuticals company [subsidiary of Accord-Fareva/Intas Pharmaceuticals], US operations headquartered in Durham NC; Accord manufactures generic carboplatin injection 10 mg/mL (50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL, 600 mg/60 mL vials) for US market distribution; manufacturing process: carboplatin API dissolution in WFI at 10 mg/mL concentration → pH check (5.0–7.0 range; no pH adjustment needed for most batches as carboplatin solution pH is naturally 5.0–6.5) → 0.22 µm sterile filtration → ISO 5 filling suite → vial fill-finish → stopper and cap → 100% visual inspection (carboplatin solution is clear and colorless) → QC release; primary exposure operations: carboplatin API weighing in negative-pressure weigh booth (HEPA exhaust; 10–20 kg per batch); filter change during filtration step (CSTD-equipped filter housings); vial fill line monitoring (fully automated; minimal operator exposure during steady-state; highest exposure at CSTD connection/disconnection for bulk solution transfer); 8-hr TWA during API weighing + fill CSTD intervention shift: actual 0.00065 mg/m³; displayed (÷10): 0.000065 mg/m³; CAS confusion event documented: EHS technician queried "carboplatin" and VelocityEHS database returned cisplatin [CAS 15663-27-1] OEL data due to a vendor database cross-reference error — same "soluble Pt 0.002 mg/m³" result but different Pt-fraction (cisplatin Pt% = 65.0% vs carboplatin Pt% = 52.4%); CAS confusion corrected on next query but VelocityEHS output identical for both]).

The Surface 2 subject is a 39-year-old female Accord Healthcare pharmaceutical manufacturing operator (11-year Accord tenure; primary duties: carboplatin API weighing, fill-line CSTD intervention, QC vial sampling; female of reproductive age — NIOSH HD Category 1 reproductive toxicant concern; VelocityEHS occupational health: annual exam (no carboplatin-specific surveillance schedule — VelocityEHS "soluble Pt" OEL output triggers only OSHA general platinum salt exposure monitoring per 1910.1020 record keeping, not HD Category 1 health surveillance); platinum IgE titer: not in current surveillance schedule (IgE sensitization monitoring applies to ionizable chloroplatinate salt workers per OSHA guidance; Accord EHS classified carboplatin as "soluble Pt compound" and scheduled IgE titer annually for API weighing personnel — but this monitors the wrong sensitization mechanism for a coordination complex and does NOT monitor HD Category 1 genotoxic/reproductive endpoints); CAS confusion incident: VelocityEHS returned cisplatin data for carboplatin query: "cisplatin [CAS 15663-27-1]: OSHA soluble Pt 0.002 mg/m³: 0.000065 × 0.650 Pt-fraction = 0.000042 mg/m³ Pt = 2.1% of limit" — nearly identical percentage to correct CAS carboplatin output, confirming interchangeable misapplication).

Surface 3 — UCSF Medical Center San Francisco CA Oncology HD Pharmacy AI

At University of California San Francisco Medical Center San Francisco CA ([505 Parnassus Avenue, San Francisco CA 94143; San Francisco County CA; UCSF Medical Center: NCI-designated comprehensive cancer center; UCSF Helen Diller Family Comprehensive Cancer Center; UCSF Pharmaceutical Services oncology pharmacy: one of the highest-volume academic medical center oncology pharmacies in the western US; carboplatin + paclitaxel (CP) protocol is the standard of care for first-line advanced ovarian cancer, first-line NSCLC with carboplatin + pemetrexed, and multiple other tumor types; UCSF oncology pharmacy prepares approximately 25–40 carboplatin infusions per day across ovarian, lung, testicular, and head/neck cancer programs; Calvert formula carboplatin dosing at UCSF: pharmacist calculates carboplatin dose per patient using Cockcroft-Gault eGFR and target AUC (AUC-5 for first-line ovarian; AUC-2 for dose-dense weekly protocols; AUC-6 for cisplatin-eligible patients choosing carboplatin): Dose [mg] = Target AUC × (GFR + 25); patient-specific doses range from 300 mg to 900 mg per cycle depending on body surface area, renal function, and protocol; preparation: USP <800> Class II Type B2 BSC; CSTD (PhaSeal or EquaShield) required for all carboplatin reconstitution and transfer steps; 8-hr TWA during high-volume carboplatin preparation shift: actual 0.00031 mg/m³; displayed (÷10): 0.000031 mg/m³; EHS Insight Pt-fraction: 0.000031 × 0.524 = 0.000016 mg/m³ Pt = 0.8% of "soluble Pt" 0.002 mg/m³]).

The Surface 3 subject is a 37-year-old female UCSF oncology pharmacist (9-year UCSF tenure; primary duties: carboplatin Calvert dose calculation (10–15 calculations per shift using Cockcroft-Gault GFR and target AUC), carboplatin reconstitution and IV bag preparation in HD BSC, CSTD connection/disconnection at drug transfer; EHS Insight occupational health: annual physical examination — carboplatin-specific health surveillance not scheduled (EHS Insight "soluble Pt 0.8% — within limit" output triggers no specific health surveillance beyond baseline); platinum IgE titer: last performed at UCSF hire (9yr ago) — no subsequent titer ordered by EHS Insight; HD Category 1 platinum hypersensitivity sensitization protocol: EHS Insight does not flag carboplatin as triggering HD-level platinum sensitization surveillance distinct from standard IgE monitoring for ionizable chloroplatinate compounds). EHS Insight: "Carboplatin [CAS 41575-94-4]: OSHA proxy — platinum, soluble salts, as Pt: 0.002 mg/m³. Measured: 0.000031 mg/m³ × 0.524 Pt = 0.000016 mg/m³ Pt = 0.8% of OSHA limit — within limit; no action required. NIOSH REL: no entry for CAS 41575-94-4. ACGIH TLV: not established." NIOSH HD Category 1 C-PEC requirement (HD BSC, which is present) verified as compliant — but EHS Insight provides no regulatory basis for this compliance; CSTD integrity (connection failure events): not tracked in EHS Insight; Calvert formula dosing architecture (patient-specific mg dose calculation per GFR) has no linkage to EHS Insight "0.8% of soluble Pt limit" output.

Integrating Glyphward into Carboplatin and Platinum Coordination Complex AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every CAS 41575-94-4 monitoring data ingestion point — before Cority at BMS Devens MA, before VelocityEHS at Accord Healthcare Durham NC, and before EHS Insight at UCSF Medical Center San Francisco CA. Threshold 21 reflects: "soluble Pt" OEL misapplication (industrial chloroplatinate catalyst OEL misapplied to therapeutic coordination complex; Pt-fraction calculation provides false compliance framing; HD Category 1 controls invisible regardless of Pt% calculation; Calvert formula AUC/GFR dosing has no air concentration correlate) + cisplatin CAS 15663-27-1 confusion (CBDCA vs CDDP; different Pt%; interchangeable "soluble Pt" output for both CAS numbers confirms systematic misapplication) [9 pts]; myelosuppression dose-limiting toxicity + genotoxicity (chromosomal aberrations in worker lymphocyte biomonitoring studies; SCE induction) + reproductive toxicant (NIOSH HD Category 1) + platinum hypersensitivity sensitization at sub-pharmacological exposure concentrations (IgE-mediated; distinct mechanism from industrial chloroplatinate sensitization but both involving platinum coordination; UCSF oncology worker platinum hypersensitivity reactions documented in clinical literature) + nephrotoxicity (reduced vs cisplatin but still present at high doses) [5 pts]; Bristol-Myers Squibb Devens MA + Accord Healthcare Durham NC + UCSF Medical Center San Francisco CA [3 pts]; FIRST carboplatin "soluble Pt" OEL misapplication AI attack (prior Glyphward platinum attack: cisplatin [#418] — carboplatin is a distinct second-generation compound with different leaving-group chemistry, Calvert dosing, and different Pt%; this is the first CBDCA-specific AI attack); FIRST Calvert formula GFR-based AUC dosing vs TWA OEL architectural incompatibility (no prior Glyphward documentation of pharmacokinetic-dosing vs OEL framework incompatibility for platinum complexes); FIRST carboplatin/cisplatin CBDCA/CDDP CAS confusion (CAS 41575-94-4 vs 15663-27-1; interchangeable "soluble Pt" output confirmed by VelocityEHS) [4 pts]. Total: 9+5+3+4 = 21.

import asyncio
import httpx

async def scan_carboplatin(cas: str, reading_mgm3: float) -> dict:
    """Scan carboplatin HD Category 1 with soluble Pt OEL misapplication detection."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,           # "41575-94-4"
                "reading_mgm3": reading_mgm3,
                "context": "hd_platinum_oncology"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, proxy_oel_misapplication, pt_fraction,
    #                    calvert_dosing_incompatible, cisplatin_cas_confusion_risk,
    #                    usp800_required, osha_pel_note

if __name__ == "__main__":
    r = asyncio.run(scan_carboplatin("41575-94-4", 0.00082))
    print(r)
    # {'hd_category': 1, 'proxy_oel_misapplication': 'soluble_platinum_industrial_catalyst',
    #  'pt_fraction': 0.524, 'calvert_dosing_incompatible': True,
    #  'cisplatin_cas_confusion_risk': True, 'usp800_required': True}